Titre : Survie sans rechute

Survie sans rechute : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Survie sans rechute : Questions médicales les plus fréquentes", "headline": "Survie sans rechute : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Survie sans rechute : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-08", "dateModified": "2025-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Survie sans rechute" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Analyse de survie", "url": "https://questionsmedicales.fr/mesh/D016019", "about": { "@type": "MedicalCondition", "name": "Analyse de survie", "code": { "@type": "MedicalCode", "code": "D016019", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N06.850.520.830.998" } } }, "about": { "@type": "MedicalCondition", "name": "Survie sans rechute", "alternateName": "Disease-Free Survival", "code": { "@type": "MedicalCode", "code": "D018572", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Inkyu Kim", "url": "https://questionsmedicales.fr/author/Inkyu%20Kim", "affiliation": { "@type": "Organization", "name": "WWHEOR, Bristol Myers Squibb, Princeton, NJ, United States." } }, { "@type": "Person", "name": "Rachel Kerr", "url": "https://questionsmedicales.fr/author/Rachel%20Kerr", "affiliation": { "@type": "Organization", "name": "Adjuvant Colorectal Cancer Group, University of Oxford, Oxford, UK." } }, { "@type": "Person", "name": "Mukta Arora", "url": "https://questionsmedicales.fr/author/Mukta%20Arora", "affiliation": { "@type": "Organization", "name": "Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota." } }, { "@type": "Person", "name": "Sandhya Gokavarapu", "url": "https://questionsmedicales.fr/author/Sandhya%20Gokavarapu", "affiliation": { "@type": "Organization", "name": "Resident, Department of Oral and Maxillofacial- Head and Neck Oncology, Shanghai Stomatology key laboratory, Ninth People's Hospital School of Medicine, Shanghai Jiao Tong University, Shanghai, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Environnement et santé publique", "item": "https://questionsmedicales.fr/mesh/D004778" }, { "@type": "ListItem", "position": 3, "name": "Santé publique", "item": "https://questionsmedicales.fr/mesh/D011634" }, { "@type": "ListItem", "position": 4, "name": "Méthodes épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D004812" }, { "@type": "ListItem", "position": 5, "name": "Statistiques comme sujet", "item": "https://questionsmedicales.fr/mesh/D013223" }, { "@type": "ListItem", "position": 6, "name": "Analyse de survie", "item": "https://questionsmedicales.fr/mesh/D016019" }, { "@type": "ListItem", "position": 7, "name": "Survie sans rechute", "item": "https://questionsmedicales.fr/mesh/D018572" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Survie sans rechute - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Survie sans rechute", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Survie sans rechute", "description": "Comment évaluer la survie sans rechute ?\nQuels tests sont utilisés pour le diagnostic ?\nQuand commence-t-on à mesurer la SSR ?\nQuels signes indiquent une rechute ?\nQuelle est l'importance du suivi régulier ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Survie sans rechute", "description": "Quels symptômes peuvent signaler une rechute ?\nLa fatigue est-elle un symptôme de rechute ?\nComment différencier les symptômes de rechute ?\nLes douleurs peuvent-elles indiquer une rechute ?\nLes changements d'appétit sont-ils significatifs ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Survie sans rechute", "description": "Comment prévenir les rechutes ?\nL'alimentation joue-t-elle un rôle dans la SSR ?\nL'exercice physique est-il bénéfique ?\nLes contrôles médicaux réguliers sont-ils importants ?\nLe soutien psychologique aide-t-il à la SSR ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Survie sans rechute", "description": "Quels traitements favorisent la SSR ?\nComment la chimiothérapie affecte-t-elle la SSR ?\nLa radiothérapie est-elle efficace pour la SSR ?\nQuels sont les effets secondaires des traitements ?\nComment le suivi post-traitement est-il organisé ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Survie sans rechute", "description": "Quelles complications peuvent survenir après traitement ?\nComment gérer les effets secondaires ?\nLes complications affectent-elles la SSR ?\nQuels sont les risques de récidive après traitement ?\nLes complications psychologiques sont-elles fréquentes ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Survie sans rechute", "description": "Quels facteurs augmentent le risque de rechute ?\nLe tabagisme influence-t-il la SSR ?\nL'hérédité joue-t-elle un rôle dans la rechute ?\nLe mode de vie influence-t-il la SSR ?\nL'âge est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D018572?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la survie sans rechute ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La SSR est évaluée par des examens cliniques et des imageries régulières après traitement." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie comme le scanner ou l'IRM et des marqueurs tumoraux peuvent être utilisés." } }, { "@type": "Question", "name": "Quand commence-t-on à mesurer la SSR ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La SSR est généralement mesurée après la fin du traitement actif, souvent 3 à 6 mois après." } }, { "@type": "Question", "name": "Quels signes indiquent une rechute ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la douleur, la fatigue ou des anomalies dans les tests peuvent indiquer une rechute." } }, { "@type": "Question", "name": "Quelle est l'importance du suivi régulier ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi régulier permet de détecter précocement une rechute et d'adapter le traitement." } }, { "@type": "Question", "name": "Quels symptômes peuvent signaler une rechute ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur persistante, fatigue accrue, et perte de poids inexpliquée." } }, { "@type": "Question", "name": "La fatigue est-elle un symptôme de rechute ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fatigue persistante peut être un signe de rechute et doit être évaluée." } }, { "@type": "Question", "name": "Comment différencier les symptômes de rechute ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Il est essentiel de consulter un médecin pour évaluer les symptômes et leur origine." } }, { "@type": "Question", "name": "Les douleurs peuvent-elles indiquer une rechute ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs nouvelles ou persistantes doivent être examinées pour une possible rechute." } }, { "@type": "Question", "name": "Les changements d'appétit sont-ils significatifs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des changements d'appétit peuvent être un signe de rechute et nécessitent une attention médicale." } }, { "@type": "Question", "name": "Comment prévenir les rechutes ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, des contrôles réguliers et le respect des traitements prescrits aident à prévenir les rechutes." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle dans la SSR ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut renforcer le système immunitaire et aider à la SSR." } }, { "@type": "Question", "name": "L'exercice physique est-il bénéfique ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la santé globale et réduire le risque de rechute." } }, { "@type": "Question", "name": "Les contrôles médicaux réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des contrôles réguliers permettent de détecter rapidement toute rechute potentielle." } }, { "@type": "Question", "name": "Le soutien psychologique aide-t-il à la SSR ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le soutien psychologique peut améliorer la qualité de vie et aider à faire face au stress." } }, { "@type": "Question", "name": "Quels traitements favorisent la SSR ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements comme la chirurgie, la chimiothérapie et la radiothérapie visent à prolonger la SSR." } }, { "@type": "Question", "name": "Comment la chimiothérapie affecte-t-elle la SSR ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chimiothérapie peut réduire la taille des tumeurs et améliorer les chances de SSR." } }, { "@type": "Question", "name": "La radiothérapie est-elle efficace pour la SSR ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la radiothérapie peut aider à éliminer les cellules cancéreuses et améliorer la SSR." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure nausées, fatigue, et immunosuppression, affectant la qualité de vie." } }, { "@type": "Question", "name": "Comment le suivi post-traitement est-il organisé ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le suivi post-traitement inclut des consultations régulières et des examens pour surveiller la SSR." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après traitement ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme l'infection, la fatigue chronique ou des effets secondaires des traitements peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des effets secondaires inclut des soins symptomatiques et un suivi médical régulier." } }, { "@type": "Question", "name": "Les complications affectent-elles la SSR ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent influencer négativement la survie sans rechute." } }, { "@type": "Question", "name": "Quels sont les risques de récidive après traitement ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les risques de récidive varient selon le type de cancer et le traitement reçu, nécessitant un suivi." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles fréquentes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications psychologiques comme l'anxiété et la dépression peuvent survenir après le traitement." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de rechute ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme le type de cancer, le stade au diagnostic et l'âge peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la SSR ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque connu qui peut affecter la survie sans rechute." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans la rechute ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de rechute." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il la SSR ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire le risque de rechute et améliorer la SSR." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge avancé peut être associé à un risque accru de rechute après traitement." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...